prikaz prve stranice dokumenta Patients with higher body mass index treated with direct / novel oral anticoagulants (DOAC / NOAC) for atrial fibrillation experience worse clinical outcomes
  Download
PDF 1.57 MB
Scientific paper - Original scientific paper
Patients with higher body mass index treated with direct / novel oral anticoagulants (DOAC / NOAC) for atrial fibrillation experience worse clinical outcomes
International Journal of Cardiology, 301 (2020); 90-95. https://doi.org/10.1016/j.ijcard.2019.10.035
Lucijanić, Marko; Jurin, Ivana; Jurin, Hrvoje; Lucijanić, Tomo; Starčević, Boris; Skelin, Marko; Glasnović, Anton; Ćatić, Jasmina; Jurišić, Anđela; Hadžibegović, Irzal

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Lucijanić, M., Jurin, I., Jurin, H., Lucijanić, T., Starčević, B., Skelin, M. ... Hadžibegović, I. (2020). Patients with higher body mass index treated with direct / novel oral anticoagulants (DOAC / NOAC) for atrial fibrillation experience worse clinical outcomes. International Journal of Cardiology, 301., 90-95. doi: 10.1016/j.ijcard.2019.10.035

Lucijanić, Marko, et al. "Patients with higher body mass index treated with direct / novel oral anticoagulants (DOAC / NOAC) for atrial fibrillation experience worse clinical outcomes." International Journal of Cardiology, vol. 301, 2020, pp. 90-95. https://doi.org/10.1016/j.ijcard.2019.10.035

Lucijanić, Marko, Ivana Jurin, Hrvoje Jurin, Tomo Lucijanić, Boris Starčević, Marko Skelin, Anton Glasnović, Jasmina Ćatić, Anđela Jurišić and Irzal Hadžibegović. "Patients with higher body mass index treated with direct / novel oral anticoagulants (DOAC / NOAC) for atrial fibrillation experience worse clinical outcomes." International Journal of Cardiology 301 (2020): 90-95. https://doi.org/10.1016/j.ijcard.2019.10.035

Lucijanić, M., et al. (2020) 'Patients with higher body mass index treated with direct / novel oral anticoagulants (DOAC / NOAC) for atrial fibrillation experience worse clinical outcomes', International Journal of Cardiology, 301, pp. 90-95. doi: 10.1016/j.ijcard.2019.10.035

Lucijanić M, Jurin I, Jurin H, Lucijanić T, Starčević B, Skelin M, and sur.. Patients with higher body mass index treated with direct / novel oral anticoagulants (DOAC / NOAC) for atrial fibrillation experience worse clinical outcomes. International Journal of Cardiology [Internet]. 2020 February 15 [cited 2024 November 27];301:90-95. doi: 10.1016/j.ijcard.2019.10.035

M. Lucijanić, et al., "Patients with higher body mass index treated with direct / novel oral anticoagulants (DOAC / NOAC) for atrial fibrillation experience worse clinical outcomes", International Journal of Cardiology, vol. 301, pp. 90-95, February 2020. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:866450. [Accessed: 27 November 2024]

Metadata
Title (english)Patients with higher body mass index treated with direct / novel oral anticoagulants (DOAC / NOAC) for atrial fibrillation experience worse clinical outcomes
AuthorMarko Lucijanić
AuthorIvana Jurin
AuthorHrvoje Jurin
AuthorTomo Lucijanić
MBZ: 18024
AuthorBoris Starčević
AuthorMarko Skelin
AuthorAnton Glasnović
AuthorJasmina Ćatić
AuthorAnđela Jurišić
AuthorIrzal Hadžibegović
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Histology and Embryology)
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Introduction: Due to fixed dosing of direct oral anticoagulants (DOACs), uncertainty exists about their efficacy in a population of obese/overweight patients. ----- Patients and methods: We retrospectively investigated a real-life cohort of 325 DOAC anticoagulated patients with atrial fibrillation [179 receiving dabigatran (55%), 74 apixaban (23%) and 72 rivaroxaban (22%)]. Patients were stratified according to the body mass index (BMI) into non-obese (233 with BMI <30 kg/m2), class I obesity (71 with BMI 30-34.9 kg/m2) and class II + obesity (21 with BMI ≥35 kg/m2). ----- Results: Patients with higher BMI receiving DOACs were more likely to experience stroke/systemic embolism sooner (P = 0.043), experience major bleeding sooner (P < 0.001) and have shorter time to composite event consisting of thrombosis, bleeding or death (P < 0.001) whereas there was no significant association with overall survival (P = 0.470). BMI was significantly associated with thrombosis but not bleeding among dabigatran treated patients, and significantly associated with bleeding but not thrombosis among patients treated with factor Xa inhibitors. Associations of higher thrombotic, bleeding and composite endpoint risks with higher BMI remained statistically significant in multivariate Cox regression models adjusted for age, gender, eGFR, CHA2DS2VASC and HAS-BLED. ----- Conclusion: Our findings indicate that obese patients receiving DOACs, especially ones with class II + obesity, might be under higher risks of stroke/bleeding depending on DOAC subtype. Loss of efficacy might be associated with dabigatran, whereas higher risk of major bleeding might be associated with factor Xa inhibitors.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionAccepted version
Journal titleInternational Journal of Cardiology
Numberingvol. 301, pp. 90-95
p-ISSN0167-5273
e-ISSN1874-1754
DOIhttps://doi.org/10.1016/j.ijcard.2019.10.035
URN:NBNurn:nbn:hr:105:866450
Publication2020-02-15
Document URLhttps://linkinghub.elsevier.com/retrieve/pii/S0167527319342603
Type of resourceText
Access conditionsOpen access
Embargo expiration date: 2021-02-17
Terms of useLicence In copyright icon
Created on2020-12-09 10:18:09